SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces an Investigation of Chiasma, Inc. - CHMA

BALA CYNWYD, Pa., June 23, 2016

Click here to learn more http://brodsky-smith.com/1093-chma-chiasma-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

The investigation concerns a securities class action lawsuit commenced in the United States District Court for the District of Massachusetts. The complaint alleges that the Defendants made false and misleading statements including failing to disclose: (1) that the Company's Phase 3 clinical trial methodology for Mycapssa was not sufficient to demonstrate efficacy and secure approval by U.S. Food and Drug Administration ("FDA"); (2) Chiasma's supervision of its suppliers was not sufficient to prevent deficiencies that would delay FDA approval of Mycapssa; and (3) as a result of the foregoing, Chiasma's public statements were materially false and misleading at all relevant times.

If you purchased shares of Chiasma between July 15, 2015 and April 17, 2016, and wish to discuss the investigation, or if you have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC before June 24, 2016, who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, by visiting http://brodsky-smith.com/1093-chma-chiasma-inc.html, or calling toll free 877-LEGAL-90.  

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders.

Attorney advertising. Prior results do not guarantee a similar outcome.